143 related articles for article (PubMed ID: 11733535)
1. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
[TBL] [Abstract][Full Text] [Related]
2. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
3. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
4. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
van der Merwe M; Bjornsti MA
J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711
[TBL] [Abstract][Full Text] [Related]
5. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
6. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
Fertala J; Vance JR; Pourquier P; Pommier Y; Bjornsti MA
J Biol Chem; 2000 May; 275(20):15246-53. PubMed ID: 10809761
[TBL] [Abstract][Full Text] [Related]
7. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
Losasso C; Cretaio E; Palle K; Pattarello L; Bjornsti MA; Benedetti P
J Biol Chem; 2007 Mar; 282(13):9855-9864. PubMed ID: 17276985
[TBL] [Abstract][Full Text] [Related]
8. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.
Colley WC; van der Merwe M; Vance JR; Burgin AB; Bjornsti MA
J Biol Chem; 2004 Dec; 279(52):54069-78. PubMed ID: 15489506
[TBL] [Abstract][Full Text] [Related]
9. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
[TBL] [Abstract][Full Text] [Related]
11. Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
Arimondo PB; Bailly C; Boutorine A; Sun JS; Garestier T; Hélène C
C R Acad Sci III; 1999 Sep; 322(9):785-90. PubMed ID: 10547719
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
13. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
[TBL] [Abstract][Full Text] [Related]
14. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
Losasso C; Cretaio E; Fiorani P; D'Annessa I; Chillemi G; Benedetti P
Nucleic Acids Res; 2008 Oct; 36(17):5635-44. PubMed ID: 18772225
[TBL] [Abstract][Full Text] [Related]
15. Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.
Hann CL; Carlberg AL; Bjornsti MA
J Biol Chem; 1998 Nov; 273(47):31519-27. PubMed ID: 9813066
[TBL] [Abstract][Full Text] [Related]
16. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Arimondo PB; Bailly C; Boutorine AS; Moreau P; Prudhomme M; Sun JS; Garestier T; Hélène C
Bioconjug Chem; 2001; 12(4):501-9. PubMed ID: 11459453
[TBL] [Abstract][Full Text] [Related]
17. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.
Jacquiau HR; van Waardenburg RC; Reid RJ; Woo MH; Guo H; Johnson ES; Bjornsti MA
J Biol Chem; 2005 Jun; 280(25):23566-75. PubMed ID: 15817450
[TBL] [Abstract][Full Text] [Related]
18. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin.
Bailly C; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M; Waring MJ
Mol Pharmacol; 1998 Jan; 53(1):77-87. PubMed ID: 9443934
[TBL] [Abstract][Full Text] [Related]
19. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.
Prudhomme M
Curr Med Chem; 2000 Dec; 7(12):1189-212. PubMed ID: 11032967
[TBL] [Abstract][Full Text] [Related]
20. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
